<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03115593</url>
  </required_header>
  <id_info>
    <org_study_id>CHUB-Hystocor</org_study_id>
    <nct_id>NCT03115593</nct_id>
  </id_info>
  <brief_title>Compare the Performance of Targeted Biopsy Versus Aspiration Biopsy With a Pipette for the Diagnosis of Endometrial Cancer</brief_title>
  <official_title>Compare the Performance of Targeted Biopsy Versus Aspiration Biopsy With a Pipette for the Diagnosis of Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brugmann University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brugmann University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endometrial cancer is the most common pelvic gynecological cancer in so-called developed&#xD;
      countries, with 320,000 new cases annually, including more than 1,500 in Belgium. It&#xD;
      preferentially affects postmenopausal women. Overall survival at 5 years is 76% but is 95%&#xD;
      for early forms, which represent more than 70% of diagnoses. The main risk factors are&#xD;
      obesity, diabetes and tamoxifen intake for breast cancer, which explains the increasing&#xD;
      incidence. Half a million new annual cases are expected in 2035.&#xD;
&#xD;
      The main symptom is postmenopausal metrorrhagia.Among these women, the prevalence of the&#xD;
      disease is estimated between 10 and 15%. Currently the recommendations are to make an&#xD;
      evaluation by endovaginal ultrasound followed by an endometrial biopsy. The histological type&#xD;
      is the main predictor of the severity of the disease and acts as guideline for the&#xD;
      treatment.It is therefore essential to have precise biopsy results before starting&#xD;
      therapeutic management.&#xD;
&#xD;
      The most widely used technique is the blind biopsy by aspiration using a pipette because it&#xD;
      is inexpensive, easy, without any specific equipment. However, recent studies showed that&#xD;
      this technique has a poor sensitivity in the target population of postmenopausal women. Other&#xD;
      studies have shown that targeted biopsies under hysteroscopic control could have a much&#xD;
      higher sensitivity.&#xD;
&#xD;
      The main objective of this study is thus to compare the performance of the targeted biopsy&#xD;
      under hysteroscopy to the performance of the biopsy by aspiration with a pipette, for the&#xD;
      diagnosis of endometrial cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of human ressources&#xD;
  </why_stopped>
  <start_date type="Actual">July 10, 2018</start_date>
  <completion_date type="Actual">March 2, 2020</completion_date>
  <primary_completion_date type="Actual">March 2, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Histological result</measure>
    <time_frame>6 months</time_frame>
    <description>Histological result (histological type and grading if cancer is diagnosed, according to the FIGO 2009 classification).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>postmenopausal patients with metrorrhagia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Postmenopausal patients with metrorrhagia and endometrial hypertrophy defined by an endometrium ticker than 3 mm (ultrasound result).&#xD;
The threshold choice of 3 mm was chosen according to a recent review of the literature to limit the risk of false negatives for cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blind biopsy with a pipette</intervention_name>
    <description>Patients willing to participate to the study will benefit from a double biopsy. The first biopsy will be a blind biopsy performed by aspiration with a Cornier pipette.</description>
    <arm_group_label>postmenopausal patients with metrorrhagia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Targeted biopsy using hysteroscopy</intervention_name>
    <description>During the same consultation, patients will benefit from a diagnostic hysteroscopy with vaginoscopy and saline (allowing a wash of the debris caused by the pipette biopsy), using a rigid hysteroscope of 4.3 mm equipped with an operator channel allowing the passage of a biopsy tong.</description>
    <arm_group_label>postmenopausal patients with metrorrhagia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  postmenopausal patient.&#xD;
&#xD;
          -  patient with postmenopausal metrorrhagia and endometrial hypertrophy defined by an&#xD;
             endometrium ticker than 3 mm (ultrasound result)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients undergoing hormone replacement therapy for menopause (THM). This treatment&#xD;
             may be the cause of benign bleeding in post menopause.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>André Nazac, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Brugmann</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Iris Sud - Site Ixelles</name>
      <address>
        <city>Brussels</city>
        <zip>1050</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Citadelle</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 11, 2017</study_first_submitted>
  <study_first_submitted_qc>April 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brugmann University Hospital</investigator_affiliation>
    <investigator_full_name>Andre Nazac</investigator_full_name>
    <investigator_title>Head of clinic</investigator_title>
  </responsible_party>
  <keyword>hysteroscopy</keyword>
  <keyword>pipette</keyword>
  <keyword>biopsy</keyword>
  <keyword>endometrial cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

